HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper

HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper

HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce it has completed, in collaboration with the Inflammatory Markers Laboratory (“IML”) located in Wichita, Kansas, a pilot study that assessed the effect of the HempFusion formulation CBD Capsules® (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test (which measures urinary 11-dehydro thromboxane B2, the stable end product of intracellular thromboxane metabolism that has been shown to correlate with inflammation) and has released a white paper titled “Oral Formulation May Modulate Thromboxane Production[i].

Results of the pilot study have shown potential promise in the area of inflammatory markers and possible effects on exaggerated inflammation.

“Our laboratory has demonstrated the effectiveness of numerous products in reducing thromboxane production,” commented Gordon Ens, Director of IML. “I was pleased to see a CBD product show such a significant reduction of thromboxane in this pilot trial.”

The white paper, expected to be published shortly, is co-authored by Gordon Ens, Director of IML and George Fritsma, Professor at University of Alabama, and illustrates the potential of tracking and elucidating biomarkers sensitive to inflammation in addition to how novel compounds and formulas modulate the expression of these markers.

Jason Mitchell, N.D., HempFusion’s Co-Founder and Chief Executive Officer commented, “We are committed to furthering research in the area of hemp-derived CBD and this pilot trial and soon to be published white paper reinforces our continued focus on the safe and effective use of hemp-derived CBD products.”

HempFusion is dedicated to research related to toxicology safety, which is evident through its involvement and co-sponsoring of the ValidCare Human Observational Safety Study, what is believed to be the largest CBD toxicology study of its kind ever completed to date. HempFusion continues to focus on research & development, pilot studies, and clinical trials, to advance the science of CBD.


HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com.

Follow HempFusion on TwitterFacebook and Instagram and Probulin on TwitterFacebook and Instagram.


Jason Mitchell, N.D.
Chief Executive Officer and Director
Email: ir@hempfusion.com
Phone: 416-803-5638


This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements“) that relate to HempFusion’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the publication of the white paper and the Company’s plans, focus and objectives.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Forward-Looking Statements” and “Risk Factors” in the final long form prospectus of the Company dated December 17, 2020 and available under the Company’s profile on SEDAR at www.sedar.com. HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release


Share - Facebook

Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Thu, 25 Mar 2021 11:42:36 +0000

Technical420 Deep Dive: There Is Still A Ton Of Value For Investors To Extract From The Cannabis Oil Trade

Technical420 Deep Dive: There Is Still A Ton Of Value For Investors To Extract From The Cannabis Oil Trade

During the last year, the cannabis industry has recorded impressive growth as new markets open across the globe. 

The opening of new markets has led to an increase in the number of export agreements, and this has greatly benefitted Canadian cannabis companies. One of the most attractive aspects of this trend is related to the amount of cannabis concentrates that are being sent to emerging international markets. 

The trend toward cannabis oil represents a shift from previous export agreements that primarily involved cannabis flower and we expect the shift to continue to trend toward cannabis oil. Prior to the legalization of cannabis derivative products in Canada (referred to as cannabis 2.0), several companies put a major emphasis on the cannabis oil markets and constructed facilities that met European Union good manufacturing practices (EU GMP) standards. 

Going forward, we expect to see consumers show a preference for products that are made from cannabis oil such as edibles, vape pens, beverages, concentrates, shatters, topicals, and more. Today, we want to highlight 5 companies that are highly focused on the cannabis oil market and believe our readers need to be aware of these operators. 

MediPharm Labs is a Misunderstood Cannabis Oil Operator

Earlier this year, we highlighted MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) as one of the most attractive Canadian cannabis oil companies. Our view on the company is based on the growth of the business in Canada and abroad, its valuation, and the potential catalysts it has for growth. 

From legal cannabis markets to the pharmaceutical sector, we believe that MediPharm represents a differentiated growth opportunity and is trading at a discount when compared to its peers. We are of the opinion that the pharmaceutical industry represents a significant opportunity for MediPharm and are favorable on how this aspect of the story has advanced. 

In January, MediPharm reported a record number of shipments of finished goods in the fourth quarter. During the quarter, the company shipped 550,000 units, and we are impressed with how the business has bounced back. When compared to the prior quarter, MediPharm reported a more than 200% increase in the number of units that were shipped. 

The number of units that were shipped does not include any international sales which we believe is an attractive vertical of the business. From Australia to South America, MediPharm has been laser focused on the international cannabis concentrate market and we consider the business to be a leader in this vertical. In the back half of the year, we expect the company to report increasing revenue growth from international markets.

Since inception, MediPharm has been focused on using state-of-the-art equipment to develop premium concentrates for businesses and consumers. As a result of the continued execution, the company has created a reputation for quality and purity, and we believe this trend supports the growth of the entire business.

During the fourth quarter, MediPharm entered into a supply agreement with Nova Scotia Liquor Corporation. The company has retail distribution agreements with six provinces (B.C., Alberta, Saskatchewan, Manitoba, Ontario and Nova Scotia) and we are bullish on the growth prospects that are associated with the domestic business.

Earlier this year, MediPharm Labs announced an important milestone and was issued a Cannabis Drug License (CDL) from Health Canada. The license is necessary for the company to manufacture and supply cannabis-based drugs. The products that are allowed with a CDL include pharmaceutical prescription drugs that have a drug identification number (DIN).

In the near-term, MediPharm is well positioned to supply cannabis based pharmaceutical drugs and active pharmaceutical ingredients (APIs) to other CDL license holders and clinical research trials for novel drug discovery. We believe the market is discounting the impact that this initiative will have on the business and find the risk-reward profile to be favorable.

Going forward, the opportunity for MediPharm with its existing pharmaceutical customers to produce existing approved cannabis drugs or to develop and manufacture new and innovative drugs through later stage clinical trials is significant. Currently, there are thousands of active cannabis focused clinical trials taking place and we expect the CDL to serve as a substantial growth driver for the business over the long-term.

We believe that MediPharm Labs is an execution story that is trading at a considerable discount. At current levels, we find the valuation to be attractive on several metrics and believe that MediPharm has a favorable risk-reward profile. Going forward, we expect the company to announce strong growth and will monitor how the story advances from here.

Aleafia Health has Been Executing on the Cannabis 2.0 Market 

Aleafia Health Inc. (AH.TO) (ALEAF) is a Canadian cannabis producer that has been highly focused on the cannabis oil market. Based on the infrastructure and facilities that are operational, the company has 50,000 kilograms of extraction capacity and is well positioned to capitalize on the cannabis oil market. We are bullish on the amount of revenue that can be generated through the company’s facilities as well as through the distribution that is already in place.

Last year, Aleafia Health became highly focused on the cannabis 2.0 opportunity and owns a diverse cannabis product portfolio that is comprised of high-margin derivative products (i.e. oils, capsules, and sprays). The portfolio has been further developed through a recent expansion to vape cartridges, sublingual strips, and ultra-high-potency CBD oil. We are favorable on the approach that Aleafia Health’s management team has employed to execute on the cannabis 2.0 market and expect this vertical to record strong growth in 2021.

In November, Aleafia Health brought its first cannabis 2.0 product to Canada’s recreational market and this is a trend that has since become more significant. The company entered the market with the launch of a vape cartridge and we are bullish on how the product has been gaining traction on the medical and recreational sides of the business.

One of the reasons why Aleafia Health is well positioned to record substantial growth is due to the amount of 2.0 products that can be created with cannabis from an outdoor operation. There is a huge difference in the quality and type of cannabis that is grown in an indoor facility and that in an outdoor facility. By using the cannabis from the outdoor operation to create derivative products, the consumer might not be able to identify the source of the cannabis that the products are derived from but will certainly recognize the quality.

Aleafia Health is executing on a multi-faceted growth strategy that is focused on ramping revenues, cutting costs, and seeing margin expansion. When it comes to the cannabis 2.0 market we are favorable on how this aspect of the business has advanced. One of the products the company sells is a US brand called Kin Slips, which utilizes a sublingual strip delivery method. This is a unique product, and we are favorable with the rapid onset time that is associated with it. Through relationships like this, Aleafia Health has been able to differentiate itself from its peers and we are favorable on how this has positioned the business for growth.

Aleafia Health is working on the production of its first edible confection product in the form of soft candies. The products were formulated and produced at the Paris Facility and should launch in the near future. We expect to see strong demand for these edible products and expect the launch to serve as a catalyst for growth.

Over the next year, Aleafia Health expects to release several new cannabis derivative products and we are favorable on the amount of revenue that can be generated by these products. Since inception, the company has focused on forming relationships with leading US cannabis brands and selling these products in Canada.

HEXO Corp. Is Out To Be The North American Beverage Leader

During the last year, HEXO Corporation (HEXO.TO) (HEXO) has become much more focused on the cannabis oil market and we attribute this to the relationship that it has with Molson Coors Inc. (TAP). The relationship is focused on developing and commercializing cannabis beverages and it needs access to a lot of cannabis oil to execute on this vertical. 

HEXO is focused on the production of CBD and THC cannabis oil and is executing on a multi-national growth strategy with Molson Coors. Initially, the cannabis beverage partnership will focus on selling CBD infused beverages in the US and THC infused beverage in Canada. The companies plan to start selling THC beverages in the US once the Federal government changes its stance on the legalization or decriminalization of cannabis. 

Going forward, we expect HEXO and Molson continue to need large quantities to execute on the cannabis beverage vertical. We expect the Canadian cannabis company to also need cannabis oil to develop and sell additional cannabis 2.0 products like edibles, vape pens, concentrates, and more. 

In 2020 we noticed a significant change in investor sentiment with HEXO and believe that the Molson Coors relationship played an important role in this. We consider the Canadian cannabis producer to be a turnaround story in the making and expect Canada’s cannabis 2.0 market to play a crucial role in this. 

What Will WeedMD Do With CX Industries?

A few years ago, we visited WeedMD’s (WMD.V) (WDDMF) state-of-the-art cultivation facility in Aylmer, Canada and were impressed with the structure of the operation. Shortly after our visit, the Canadian cannabis company announced that it would put a major focus on the cannabis oil market and formed CX Industries Inc. to do so. 

CX Industries specializes in extraction, toll processing and third-party product formulation from its fully licensed facility in Aylmer. Last year, the company announced that CX plans to process more than 50,000 kilograms of biomass per year (when it is operating at peak production). When we first learned about the launch of the division, we were favorable on the plan for the business unit to capitalize on a burgeoning market ahead of the legalization of cannabis 2.0 products in Canada. 

Last year, WeedMD issued an update on CX and reported that it is offering tolling and white labelling services to other Canadian cannabis producers and brands. Last year, two Vitalis Q90 extractors at CX Industries were installed to commercialize products and we are waiting to learn more about this division of the business. 

During the last year, WeedMD has been under considerable pressure and the market seems to have lost faith in it. The company has been negatively impacted by a change in management team, less than optimal performance by the outdoor facility, and more limited access to equity capital. We are cautiously optimistic with WeedMD and will monitor how the story evolves from here. 

Aphria and Tilray are Positioned to be a Market Leader

In late 2020, Tilray Inc. (TLRY) shocked the market when it announced a merger agreement with Aphria Inc. (APHA.TO) (APHA). The combined company would be well positioned to capitalize on the global cannabis market and will be one of the largest producers of cannabis oil. 

The combined company would be expected to take a leadership position in Canada and we are bullish on the potential synergies that could be found between the operators. Aphria has been highly focused on the Canadian and the international cannabis opportunities and we are favorable on the amount of distribution that it has in the EU.

As it relates to the cannabis derivative product market, both Aphria and Tilray represent attractive opportunities. Prior to the merger announcement, Aphria acquired Sweetwater Brewing Company and we are favorable on how the asset positions the business to capitalize on the US market. 

To make cannabis beverages, a company needs to have access to cannabis oil and we are favorable on how the combined company will be positioned to capitalize on this vertical. Going forward, we expect the combined company to start selling cannabidiol (CBD) beverages in the US and are favorable on the direction the business is heading. 

Since inception, Tilray has been highly focused on the Canadian medical cannabis market and strategic international markets. Many of the products that will be sold by the combined company will be created with cannabis oil and we will monitor how the story advances this year. 


Share - Facebook

Share - Twitter

Published at Tue, 23 Mar 2021 11:37:04 +0000

2 Marijuana Stocks To Watch Before April

2 Marijuana Stocks To Watch Before April

2 Marijuana Stocks To Watch Before April | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

Published at Sun, 21 Mar 2021 20:43:57 +0000

Canopy Growth Announces US$750 Million Term Loan Financing

Canopy Growth Announces US$750 Million Term Loan Financing

Canopy Growth Corporation (“Canopy Growth” or “Canopy” or the “Company”) (TSX: WEED) (NASDAQ: CGC) is pleased to announce that it has entered into a credit agreement (the “Credit Agreement”)  with Funds advised by King Street Capital Management, L.P. (“King Street”). Under the Credit Agreement, the Company has raised a US$750 million senior secured term loan (the “Term Loan Facility”). The Company also has the ability to obtain up to an additional US$500 million of incremental senior secured debt pursuant to the Credit Agreement.

Logo: Canopy Growth Corporation (CNW Group/Canopy Growth Corporation)

“We are delighted to welcome King Street as our anchor debt investor and look forward to building value for both our credit and equity investors over time,” said Mike Lee , EVP and CFO of Canopy Growth. “This transaction further strengthens Canopy’s balance sheet, provides additional capital to invest in high-return growth opportunities, and marks a key milestone for us as we work towards achieving a more efficient capital structure”.

“We have been impressed with the growth of Canopy as a leader in the Canadian market and look forward to providing this strategic capital as Canopy further expands its business,” said Noah Charney , Managing Director at King Street.

The Term Loan Facility has no amortization payments and matures on March 18, 2026 . The gross proceeds, net of fees and expenses, will be used by Canopy Growth for working capital and general corporate purposes, including without limitation, growth investments, acquisitions, capital expenditures, and strategic initiatives. The Term Loan Facility has a coupon of LIBOR plus 8.50% and is subject to a LIBOR floor of 1.00%. Giving effect to the net proceeds from the Term Loan Facility, the Company’s estimated pro forma cash, cash equivalents and short-term investments position as at December 31, 2020 would have been approximately CAD$2.5 billion .

Greenhill & Co. acted as financial advisor to Canopy Growth. Cassels Brock & Blackwell LLP acted as Canadian counsel to Canopy Growth, and Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as US counsel to Canopy Growth. Goodmans LLP acted as Canadian counsel and Davis Polk & Wardwell LLP acted as US counsel to King Street.

About Canopy Growth

Canopy Growth (TSX: WEED , NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States , and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com .

About King Street

King Street is an $18 billion global investment management firm founded in 1995 with offices in New York , London , Singapore , Tokyo andCharlottesville, VA . King Street employs a fundamental, research-intensive approach across multiple strategies, markets, industries and asset classes including an expanding lending platform.

Notice Regarding Forward Looking Statements

This press release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable U.S. and Canadian securities laws (collectively, “forward-looking statements”), which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as “intend,” “goal,” “strategy,” “estimate,” “expect,” “project,” “projections,” “forecasts,” “plans,” “seeks,” “anticipates,” “potential,” “proposed,” “will,” “should,” “could,” “would,” “may,” “likely,” “designed to,” “foreseeable future,” “believe,” “scheduled” and other similar expressions. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Forward–looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those forward–looking statements and the forward-looking statements are not guarantees of future performance. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. A discussion of some of the material factors applicable to the Company can be found under the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, filed with the Securities and Exchange Commission and with applicable Canadian securities regulators, as such factors may be further updated from time to time in its periodic filings with the Securities and Exchange Commission and with applicable Canadian securities regulators, which can be accessed at www.sec.gov/edgar and www.sedar.com , respectively. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in the filings. Any forward–looking statement included in this press release is made as of the date of this press release and, except as required by law, the Company disclaims any obligation to update or revise any forward-looking statement. Readers are cautioned not to put undue reliance on any forward-looking statement. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement


View original content to download multimedia: http://www.prnewswire.com/news-releases/canopy-growth-announces-us750-million-term-loan-financing-301250141.html

SOURCE Canopy Growth Corporation

Published at Thu, 18 Mar 2021 11:39:47 +0000

Aleafia Health Expands Adult-use Presence with Entrance in Saskatchewan, new Provincial Market

Aleafia Health Expands Adult-use Presence with Entrance in Saskatchewan, new Provincial Market

Aleafia Health Inc. (TSX: AH, OTC: ALEAF) is pleased to announce that its products are now available to consumers in Saskatchewan. The initial provincial launch includes a broad array of Aleafia Health’s cannabis product portfolio, including sublingual strips, cannabis oils, dried flower, and vape cartridges. The Company’s adult-use products are now available in four provinces representing 67 per cent of the Canadian population.

“The expansion into this new market is part of a much broader adult-use strategy that we continue to accelerate through the launch of exciting new product formats,” said Aleafia Health CEO Geoffrey Benic. “We are excited to begin expanding our presence in Saskatchewan, a province which boasts a well-earned reputation for a business and consumer-friendly cannabis regulatory regime.”

This follows the launch of Aleafia Health’s Canadian cannabis portfolio Sunday Market. Under the Sunday Market family are four new distinct brands, including the cannabis edibles brand Bogart’s Kitchen, which launched with THC Soft Chews in March 2020.

For Investor & Media Relations:

Nicholas Bergamini, VP Investor Relations
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.

Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.


Share - Facebook

Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Tue, 16 Mar 2021 11:52:30 +0000

Aphria Inc. (APHA) to Host Special Meeting of Shareholders on Wednesday, April 14, 2021

Aphria Inc. (APHA) to Host Special Meeting of Shareholders on Wednesday, April 14, 2021

Aphria Inc. (APHA) to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

Published at Mon, 15 Mar 2021 13:19:47 +0000

Can You Make Money With Marijuana Stocks? 2 To Watch Right Now

Can You Make Money With Marijuana Stocks? 2 To Watch Right Now

Can You Make Money With Marijuana Stocks? 2 To Watch Right Now | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

Published at Fri, 12 Mar 2021 14:50:39 +0000

Time to load up on Square Inc (NYSE:SQ)

Time to load up on Square Inc (NYSE:SQ)

The tech stocks sold off due to rising rate fears. However, U.S. stock futures rose sharply in early morning trading on Monday, as Treasury yields retreated from their highs from last week, easing concerns about inflation and that higher rates would undermine equity valuations. Investors have a “rare” opportunity to buy the dip here, according to Mizuho analyst Dan Dolev.

The mobile payment company is coming off mixed fourth-quarter results earlier this week where the company revealed it purchased $170 billion worth of Bitcoin.

Shares finished the week down almost 17% but Dolev believes Square is in good shape for the long run.

The company’s bitcoin-enabled Cash App is “holding up well” and should continue to see growth after some recent deceleration, he wrote. The app allows users to transfer money via a mobile phone app.

“We see overall Seller & Cash App gross profit accelerating in 1Q21,” he said.

And according to Dolev, the company’s products are “highly levered” to any government stimulus if more should transpire as is expected.

“Following the stimulus in March 2020, Cash App gross profit growth accelerated,” Dolev said.

The firm also has a Street high price target of $380 per share and even though the stock sold off this week, Square’s momentum remains firmly well-positioned, he said.

Source: https://www.cnbc.com/

Published at Mon, 01 Mar 2021 14:02:02 +0000

New York Lawmaker Files Bill To Decriminalize Psilocybin Mushrooms

New York Lawmaker Files Bill To Decriminalize Psilocybin Mushrooms

A New York lawmaker is proposing to decriminalize psychedelic mushrooms in the state.

Assemblywoman Linda Rosenthal (D) introduced the reform legislation on Monday. It would amend state statute by removing psilocybin and psilocin—two of the main psychoactive ingredients in so-called magic mushrooms—from the list of controlled substances.

This is similar to a bill Rosenthal filed last year, except that the old version only covered psilocybin while the new one also includes psilocin. The measure has now been referred to the Assembly Health Committee.

A “justification” section of the legislation notes that research shows psilocybin has significant potential to help treat mental health conditions such as severe depression, anxiety and addiction. It also lists cities that have already moved to decriminalize the psychedelic and says “New York should do the same.”

Read More

Published at Tue, 09 Mar 2021 21:55:00 +0000

Cannabis Legalization Discussions Continue to Heat Up in Wisconsin Following Gov. Tony Evers’ Budget Proposal

Cannabis Legalization Discussions Continue to Heat Up in Wisconsin Following Gov. Tony Evers’ Budget Proposal

Today is International Women’s Day—an opportunity to celebrate women have chosen to challenge the status quo, helping break down barriers for themselves and others. It’s also a moment where we look toward the future with hope for all the more we can achieve for women around the world by working together.

Each year on March 8, we honor this tradition by highlighting the women of Cannabis Conference, an impressive roster of women shattering glass ceilings, making space for themselves and other notable women in the burgeoning cannabis industry.  

This listing is just a start. As we continue to announce speakers for Cannabis Conference (Aug. 24-26, 2021, at the Paris Las Vegas Hotel & Casino), there will be plenty more women innovators, leaders, entrepreneurs and trailblazers to highlight—so keep an eye on CannabisConference.com for continued updates to our speaker roster.



Theresa Bennett

Editor, Hemp Grower

Theresa Bennett is editor of Hemp Grower. She joined HG and Cannabis Business Times as associate editor in November 2019 after working for GIE Media’s Recycling Group of magazines. Prior to her time with GIE, Bennett was the K-12 education reporter for the Akron Beacon Journal. Bennett is also a freelance writer whose work has appeared in Modern Farmer and newspapers across the country.



Salpy Boyajian

Executive Vice President / Board Chairman, Flower One

Salpy Boyajian joined Flower One in October of 2018 following the acquisition of NLV Organics (NLVO), a renowned consumer brand and luxury cultivator she co-founded in 2014. Boyajian now serves as the company’s Executive Vice President and Board Chairman, having previously held the title of Chief Operating Officer. Before entering the cannabis space, she served as the Mental Health Director for several leading non-profits in Los Angeles, ultimately founding her own non-profit organization before relocating to Nevada.



Debby Goldsberry
Executive Director, Magnolia Wellness, FLOR
Co-Founder, Berkeley Patients Group collective 

Debby Goldsberry is executive director at Magnolia Wellness, an award-winning dispensary in Oakland, Calif., and the managing director of the Berkeley Community Care Center dispensary at Amoeba Music. She co-founded the Berkeley Patients Group (BPG) medical cannabis collective in 1999, directing its growth for more than 11 years. In 2017, Goldsberry published her first book, “Idiot’s Guide: Starting and Running a Marijuana Business.”



Emily Kowalski
Vice President of Cultivation, LeafLine Labs

Emily Kowalski is the Vice President of Cultivation at LeafLine Labs, LLC, one of two medical cannabis companies serving the patients of Minnesota. She utilizes her 10-plus years of experience in propagation, greenhouse production, and outdoor nursery production to cultivate consistent, healthy cannabis in LeafLine’s state-of-the-art indoor facility. Kowalski never settles for status quo and digs deep into data to drive quality and efficiency within her operation.

Neiden Tomaselli

Cassie Neiden Tomaselli

Conference Programming Director, Cannabis Conference

Contributing Editor, Cannabis Business Times, Cannabis Dispensary and Hemp Grower

Cassie Neiden Tomaselli is a media professional with 10+ years’ experience generating print, web, video and podcast content for both trade and consumer markets. She now serves as Conference Programming Director for Cannabis Conference, where she works with the event’s Advisory Board and editorial teams from Cannabis Business Times, Cannabis Dispensary and Hemp Grower to craft high-quality education for industry events. Previously, Neiden Tomaselli served as Director of Marketing & Communications for Firelands Scientific, an Ohio-based medical cannabis company.



Alisia Ratliff, PMP
Chief Executive Officer & Founder, Victus Capital Ventures, LLC

Alisia Ratliff, the CEO of Victus Capital Ventures and licensed project management professional, is a technical conference speaker, esteemed author, and ambitious entrepreneur. Possessing over 14 years of leadership experience expanding over several industries—Ratliff effectively manages technical and executive teams cross-departmentally while simultaneously overseeing all business operations, including supply chain, manufacturing, laboratory operations and product formulation. Ratliff helps her clients avoid repeating failed business models and implement sustainable business strategies no matter the ever-changing regulatory environment.



Andriana Ruscitto

Assistant Editor, Cannabis Business Times, Cannabis Dispensary, Hemp Grower

Andriana Ruscitto was hired as an associate editor for Cannabis Business Times, Cannabis Dispensary and Hemp Grower in January 2021. Before joining GIE, Ruscitto attended Kent State University, where she worked in the university communications and marketing department, writing stories for the Kent State Today.



Melissa Schiller

Senior Digital Editor, Cannabis Business Times & Cannabis Dispensary

Melissa Schiller joined the Cannabis Business Times team as an Assistant Digital Editor in June 2017 and now serves as Senior Digital Editor. Previously, she worked as an Audience Development Associate for GIE Media’s Ornamental Group of publications, where she managed the circulation for Cannabis Business Times, Garden Center, Nursery Management, and Greenhouse Management. She has also worked as a contributing writer and editorial assistant for a community newspaper and as a freelance writer for Northeast Ohio Media Group and Modern Tire Dealer.



Anna Shreeve
President, Urban Paragon, Inc., Targeted Intent, Inc., and The Bakeréé

Anna Shreeve is President of Urban Paragon, Inc., Targeted Intent, Inc., and The Bakeréé. Shreeve entered the medical cannabis industry seven years ago with her son, and she and her team opened The Baker, a division of Cookie Fam Genetics, a collaboration with legendary breeder “Jigga.” Shreeve’s group holds two recreational producer/processor licenses in Washington, and a recreational retail/processor license in Oregon.



Michelle Simakis

Editor, Cannabis Business Times

Michelle Simakis is editor of Cannabis Business Times. She joined GIE Media in 2012 and most recently served as editor of Garden Center magazine, the leading trade publication covering the independent garden retail market. Under her direction, Garden Center expanded its Top 100 Independent Garden Centers List by devoting an entire issue to telling the stories of the leaders and companies ranked on the list. She also helped to launch the Garden Center Executive Summit, the educational conference for key-decision makers in the industry, and recently developed a the only daily e-newsletter in the market.



Noelle Skodzinski

Editorial Director, Cannabis Business Times, Cannabis Dispensary, Hemp Grower, Cannabis Conference

Noelle Skodzinski has 25+ years of publishing experience. She co-founded Cannabis Business Times with previous owner Tim Hermes in 2014. She has been named among the Top 50 Most Influential Women in Cannabis. Previously, she held numerous editorial leadership roles, including serving as editorial director of the Publishing Group at North American Publishing Co., where she oversaw two national business magazines, all digital content products, as well as the annual Publishing Business Conference and related events. In 2018 and 2020, Skodzinski was named one of the “Top Women in Media” by Folio.  





Hope Wiseman
Owner, Mary & Main Dispensary

Born and raised in Prince George’s County, Md., Hope Wiseman has always been passionate about serving her community. After spending a year at SunTrust as an Equity Institutional Sales Analyst, Wiseman decided to continue striving for excellence by pursuing her dreams of entrepreneurship. In Fall 2017, Wiseman became the youngest Black woman dispensary owner in the United States with the opening of Mary & Main dispensary in Prince George’s County, Maryland. She has been featured in Black Enterprise, Huffington Post, Blavity, and Cannabis Dispensary. Wiseman is also a speaker and consultant to those looking to enter the industry.

Published at Mon, 08 Mar 2021 14:00:00 +0000